OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Works matching IS 03331024 AND DT 2016 AND VI 36 AND IP 9
Results: 10
1
2
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
- Published in:
- 2016
- By:
- Publication type:
- journal article
3
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
- Published in:
- 2016
- By:
- Publication type:
- journal article
4
Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
- Published in:
- 2016
- By:
- Publication type:
- journal article
5
Re: Occipital nerve block for the short-term prevention of migraine.
- Published in:
- 2016
- By:
- Publication type:
- Letter
6
Reply to Dr. Merry's Letter to the Editor.
- Published in:
- 2016
- By:
- Publication type:
- Letter
7
Variability of the characteristics of a migraine attack within patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
8
The modulatory effect of anandamide on nitroglycerin-induced sensitization in the trigeminal system of the rat.
- Published in:
- 2016
- By:
- Publication type:
- journal article
9
Test-retest reliability of visual-evoked potential habituation.
- Published in:
- 2016
- By:
- Publication type:
- journal article
10
Migraine and subclinical atherosclerosis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
- Published in:
- 2016
- By:
- Publication type:
- journal article